HIV Incidence Rate
INDICATION & LIMITATION OF USE

DESCOVY® for HIV-1 pre-exposure prophylaxis (PrEP) is indicated in at-risk adults and adolescents (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at risk from receptive vaginal sex. HIV-1–negative status must be confirmed immediately prior to initiation.

Limitation of Use: DESCOVY FOR PrEP® is not indicated in individuals at risk of HIV-1 from receptive vaginal sex because effectiveness in this population has not been evaluated.

Nearly all patients remained HIV-free with DESCOVY®1,2

DESCOVY FOR PrEP® was noninferior to FTC/TDF

At primary analysis

  • HIV incidence rate of 0.16/100 PY vs 0.34/100 PY (IRR=0.47; CI: 0.19-1.15)

At ≥96 weeks

  • HIV incidence rate of 0.16/100 PY vs 0.30/100 PY (IRR=0.54; CI: 0.23-1.26)

DESCOVY (n=2670)

99.7%

FTC/TDF (n=2665)

99.4%

OF PATIENTS REMAINED HIV-FREE

AT PRIMARY ANALYSIS AND ≥96 WEEKS


  • Primary analysis: When 100% of patients reached Week 48 and ≥50% reached Week 96

Treatment outcomes were similar across subgroups of age, race, gender identity, and baseline FTC/TDF use.

Seroconversions

FTC/TDF=emtricitabine/tenofovir disoproxil fumarate; IRR=incidence rate ratio; PY=person-years.